VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
52 hedge funds and large institutions have $138M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2015 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 10 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
53% more funds holding
Funds holding: 34 → 52 (+18)
14% more capital invested
Capital invested by funds: $120M → $138M (+$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.92M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.44M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.31M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$684K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$451K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$344K |
VTAE Hedge Fund Activity: Q1 2015 in Review
52 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q1 2015, worth a combined $138M — up 14% from $120M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VTAE positions and 10 closed out — a net gain of 18 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $15.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.44M sold.
- 52 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q1 2015, up from 34 in Q4 2014.
- Funds reported $138M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q1 2015, up 14% quarter-over-quarter.
- 28 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q1 2015 and 10 closed out, a net change of +18 holders.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q1 2015 was Fidelity Investments, an estimated $15.9M added.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q1 2015 was EcoR1 Capital, an estimated $3.44M sold.
Based on aggregated 13F filings for Q1 2015.